Quantifying Protective Immunity Through Functional Neutralization Assays

This direction is merged into another direction: pseudovirus neutralization assay. Its last version stays readable and citable here.

Version 1 of 114 papers15 conceptsfrozen 2026-10-04

In the study of viral outbreaks and vaccine efficacy, there is a critical distinction between the presence of an antibody and its potency. While standard blood tests can detect whether an individual has developed antibodies against a virus, these tests often measure simple binding—the ability of an antibody to stick to a viral protein. However, sticking is not the same as stopping. To understand if a person is actually protected, researchers look to functional neutralization assays, which measure the biological capacity of serum to actively block a virus from infecting cells.

The Mechanism of Functional Neutralization

The intuition behind a functional assay is to simulate a "mini-infection" in a controlled environment. Instead of just looking for the physical presence of proteins, researchers like Mai‐Juan Ma and Jing Bao use assays that measure the ability of serum to prevent viral replication within cell cultures.

Several techniques serve as the "gold standard" for this measurement:

  • Hemagglutination Inhibition (HI) Assay: Used extensively in influenza research, this technique exploits the fact that flu viruses clump red blood cells together. As Ming Wang and Jun Yuan demonstrate, if antibodies are functional, they will coat the virus and prevent this clumping.
  • Plaque Reduction Neutralization Test (PRNT): This involves mixing a virus with a patient's serum and adding it to a layer of host cells. Researchers like Frederica Dedo Partey count the number of "plaques" (areas of cell death); a reduction in plaques indicates the serum's neutralizing power.
  • Microneutralization and CPE Assays: These measure the "cytopathic effect" (CPE)—the structural changes in host cells caused by viral invasion. Fuzhen Wang and Baoying Huang used these to track how long COVID-19 vaccines remain effective by observing the specific dilution level required to inhibit viral activity.

Establishing Correlates of Protection

The ultimate goal of these assays is to find a "correlate of protection"—a specific numerical threshold of antibodies that predicts a person is safe from disease. For example, in influenza studies, Ying Deng and Peng Yang utilized a 1:40 HI titre threshold to define protective immunity in the Beijing population.

In the context of COVID-19, Youyi Fong and Adrian B. McDermott analyzed the ENSEMBLE trial to identify biomarkers that predict vaccine efficacy. By correlating neutralization levels with clinical outcomes, they moved beyond "yes/no" immunity toward a precise predictor of risk for moderate-to-severe infection.

Tracking the Antibody Shelf-Life

Functional assays are essential for understanding how immunity wanes over time. Research into the 2009 H1N1 pandemic by Ming Wang found that protective immunity can "drop off a cliff," with half of the study participants losing sufficient functional antibodies within six months.

However, long-term studies of SARS-CoV-2 survivors by Dan Liang and Cesheng Li suggest a more complex trajectory. While functional antibodies decline initially, they often stabilize around the nine-month mark, and in some cases, neutralizing titers even increase late in the first year, suggesting the maturation of immune memory.

Measuring Evasion and the Future of Testing

When new variants emerge, functional assays quantify exactly how much "immune escape" has occurred. Xiantao Zhang and Shijian Wu used these tests to show that the Omicron variant significantly eroded the neutralizing capacity of convalescent sera compared to previous strains.

Because live-virus assays are slow and require high-security labs, researchers are developing faster alternatives. Haojie Wang and Jianxing Chen have pioneered "pseudovirus" assays, which use harmless viruses engineered to carry the spike protein of a dangerous pathogen. These provide a safe, high-throughput way to measure neutralization, bridging the gap between the speed of simple protein-binding tests and the biological accuracy of live-virus challenges.

Papers in this version

History & citationVersion 1 · 2026-10-04

Merged into another direction · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_quantifying_protective_immunity_through__4f7a23f7,
  title = {Quantifying Protective Immunity Through Functional Neutralization Assays},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/quantifying-protective-immunity-through-functional-neutralization-assays/rdr_4f7a23f7d43c4678a2e516180423e48d},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_quantifying_protective_immunity_through__4f7a23f7_v1,
  title = {Quantifying Protective Immunity Through Functional Neutralization Assays},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/quantifying-protective-immunity-through-functional-neutralization-assays/rdr_4f7a23f7d43c4678a2e516180423e48d/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}